Clinical Trial Update: KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting [Phase 2]

View source ↗

Summary

Kumquat Biosciences is conducting a Phase 2 trial evaluating KQB198 in combination with imatinib as first-line therapy for advanced or metastatic gastrointestin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib (imatinib)
• KQB198

Snippet

Sponsor: Kumquat Biosciences Inc. | Conditions: GIST - Gastrointestinal Stromal Tumor, GIST | Phase 2 | Status: RECRUITING